Express News | Aditxt Inc - Enters Securities Purchase Agreement With Evofem Biosciences - SEC Filing

ReutersApr 9 17:18 ET

10-K/A: Annual report (Amendment)

SECMar 28 16:05 ET · Announcements

Evofem Partners With Windtree Therapeutics to Slash PHEXXI Manufacturing Costs By 55%-60% Through New License And Supply Agreement; There Will Be No Cost To Evofem For The Tech Transfer To The New Manufacturer Engaged By Windtree.

BenzingaMar 26 08:49 ET

Express News | Evofem Expects Significant Reduction in Phexxi Manufacturing Cost Through Agreement With Windtree Therapeutics

ReutersMar 26 08:47 ET

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics

PR NewswireMar 26 08:47 ET

Evofem Biosciences GAAP EPS of -$0.03, Revenue of $7.1M

Seeking AlphaMar 24 08:52 ET